Literature DB >> 6409481

Changes in T-cell subsets in patients with rheumatoid arthritis treated with total lymphoid irradiation.

B L Kotzin, G S Kansas, E G Engleman, R T Hoppe, H S Kaplan, S Strober.   

Abstract

Patients with intractable rheumatoid arthritis (RA) were treated with total lymphoid irradiation (TLI, 2000 rads). We previously reported long-lasting clinical improvement associated with marked suppression of in vitro lymphocyte function in this group. In an attempt to better understand the mechanism of immunosuppression and clinical changes observed after TLI, we studied in greater detail changes in peripheral blood T-cell subsets identified by monoclonal antibodies. Before TLI, RA patients had a higher percentage of Leu-3 (helper subset) cells and a lower percentage of Leu-2 (suppressor/cytotoxic subset) cells than normals. Immediately after TLI, the absolute numbers of both Leu-2 and Leu-3 cells were reduced by at least 90%. Within 6-12 weeks, the number of Leu-2 cells returned to the pretreatment levels, but the levels of Leu-3 cells remained depressed for months thereafter. The lack of repopulation of Leu-3 cells resulted in a marked increase in the ratio of Leu-2 to Leu-3 cells as compared to pretreatment values (1.73 +/- 0.23 vs 0.39 +/- 0.06), and in a decrease in the percentage and absolute number of total T (Leu-1 and Leu-4) cells. The failure of Leu-3 cells (which mediate predominantly helper/inducer functions) to repopulate the peripheral blood may contribute to the prolonged clinical immunosuppression observed after TLI. Similar changes in T-cell subsets were not observed in RA patients given remittive drugs or low doses (200 rads) of radiotherapy. Thus, TLI differs from other treatment modalities with regard to its prolonged selective effect on the Leu-3 subset.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6409481     DOI: 10.1016/0090-1229(83)90075-2

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  8 in total

1.  Activation pathways of synovial T lymphocytes. Expression and function of the UM4D4/CDw60 antigen.

Authors:  D A Fox; J A Millard; L Kan; W S Zeldes; W Davis; J Higgs; F Emmrich; R W Kinne
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

2.  Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration.

Authors:  R J Verburg; R Flierman; J K Sont; F Ponchel; L van Dreunen; E W Levarht; M M Welling; R E M Toes; J D Isaacs; J M van Laar
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

3.  Lymphoid irradiation in intractable rheumatoid arthritis: effects on the production of immunoglobulins and rheumatoid factors.

Authors:  J G Hanly; J Hassan; M Moriarty; A Whelan; C Feighery; B Bresnihan
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

4.  Human peripheral blood monocytes display surface antigens recognized by monoclonal antinuclear antibodies.

Authors:  V M Holers; B L Kotzin
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

Review 5.  Clinical applications of monoclonal antibodies.

Authors:  H Krakauer
Journal:  Eur J Clin Microbiol       Date:  1985-02       Impact factor: 3.267

6.  Blood lymphocyte subsets after the first fraction in patients given hyperfractionated total body irradiation for bone marrow transplantation.

Authors:  T Girinsky; G Socie; J M Cosset; E P Malaise
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

7.  Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4.

Authors:  D Wofsy; W E Seaman
Journal:  J Exp Med       Date:  1985-02-01       Impact factor: 14.307

8.  Regulation of gene expression in autoimmune disease loci and the genetic basis of proliferation in CD4+ effector memory T cells.

Authors:  Xinli Hu; Hyun Kim; Towfique Raj; Patrick J Brennan; Gosia Trynka; Nikola Teslovich; Kamil Slowikowski; Wei-Min Chen; Suna Onengut; Clare Baecher-Allan; Philip L De Jager; Stephen S Rich; Barbara E Stranger; Michael B Brenner; Soumya Raychaudhuri
Journal:  PLoS Genet       Date:  2014-06-26       Impact factor: 5.917

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.